Potential future therapies: Natriuretic peptides

Ondrej Lisy, John C Jr. Burnett

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Congestive heart failure has become a major public health problem. A hallmark of this syndrome is neurohumoral activation, with elevation of natriuretic peptides, in particular atrial natriuretic peptide and brain natriuretic peptide of myocardial origin, which occurs with the onset of ventricular dysfunction. The natriuretic peptide system is important in cardiorenal regulation, specifically in the integrated control of intravascular volume and arterial pressure to maintain optimal circulatory integrity. Several therapeutic approaches have been established to mimic or potentiate the unique cardiovascular and renal beneficial actions of these peptides during heart failure. Recent investigations have also established a diagnostic utility for the natriuretic peptides to diagnose early asymptomatic left ventricular dysfunction. Thus, diagnostic and therapeutic use of the natriuretic peptides is emerging as a new strategy to delay the natural history of progressive heart failure from its earliest phase to chronic congestive heart failure.

Original languageEnglish (US)
Pages (from-to)389-394
Number of pages6
JournalCoronary Artery Disease
Volume10
Issue number6
StatePublished - 1999

Fingerprint

Natriuretic Peptides
Heart Failure
Ventricular Dysfunction
Brain Natriuretic Peptide
Left Ventricular Dysfunction
Atrial Natriuretic Factor
Therapeutic Uses
Therapeutics
Arterial Pressure
Public Health
Kidney
Peptides

Keywords

  • Congestive heart failure
  • Early asymptomatic left ventricular dysfunction
  • Natriuretic peptides
  • Neutral endopeptidase

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Potential future therapies : Natriuretic peptides. / Lisy, Ondrej; Burnett, John C Jr.

In: Coronary Artery Disease, Vol. 10, No. 6, 1999, p. 389-394.

Research output: Contribution to journalArticle

@article{3dc183ba87ec4ce9a8f99b79b2528c92,
title = "Potential future therapies: Natriuretic peptides",
abstract = "Congestive heart failure has become a major public health problem. A hallmark of this syndrome is neurohumoral activation, with elevation of natriuretic peptides, in particular atrial natriuretic peptide and brain natriuretic peptide of myocardial origin, which occurs with the onset of ventricular dysfunction. The natriuretic peptide system is important in cardiorenal regulation, specifically in the integrated control of intravascular volume and arterial pressure to maintain optimal circulatory integrity. Several therapeutic approaches have been established to mimic or potentiate the unique cardiovascular and renal beneficial actions of these peptides during heart failure. Recent investigations have also established a diagnostic utility for the natriuretic peptides to diagnose early asymptomatic left ventricular dysfunction. Thus, diagnostic and therapeutic use of the natriuretic peptides is emerging as a new strategy to delay the natural history of progressive heart failure from its earliest phase to chronic congestive heart failure.",
keywords = "Congestive heart failure, Early asymptomatic left ventricular dysfunction, Natriuretic peptides, Neutral endopeptidase",
author = "Ondrej Lisy and Burnett, {John C Jr.}",
year = "1999",
language = "English (US)",
volume = "10",
pages = "389--394",
journal = "Coronary Artery Disease",
issn = "0954-6928",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Potential future therapies

T2 - Natriuretic peptides

AU - Lisy, Ondrej

AU - Burnett, John C Jr.

PY - 1999

Y1 - 1999

N2 - Congestive heart failure has become a major public health problem. A hallmark of this syndrome is neurohumoral activation, with elevation of natriuretic peptides, in particular atrial natriuretic peptide and brain natriuretic peptide of myocardial origin, which occurs with the onset of ventricular dysfunction. The natriuretic peptide system is important in cardiorenal regulation, specifically in the integrated control of intravascular volume and arterial pressure to maintain optimal circulatory integrity. Several therapeutic approaches have been established to mimic or potentiate the unique cardiovascular and renal beneficial actions of these peptides during heart failure. Recent investigations have also established a diagnostic utility for the natriuretic peptides to diagnose early asymptomatic left ventricular dysfunction. Thus, diagnostic and therapeutic use of the natriuretic peptides is emerging as a new strategy to delay the natural history of progressive heart failure from its earliest phase to chronic congestive heart failure.

AB - Congestive heart failure has become a major public health problem. A hallmark of this syndrome is neurohumoral activation, with elevation of natriuretic peptides, in particular atrial natriuretic peptide and brain natriuretic peptide of myocardial origin, which occurs with the onset of ventricular dysfunction. The natriuretic peptide system is important in cardiorenal regulation, specifically in the integrated control of intravascular volume and arterial pressure to maintain optimal circulatory integrity. Several therapeutic approaches have been established to mimic or potentiate the unique cardiovascular and renal beneficial actions of these peptides during heart failure. Recent investigations have also established a diagnostic utility for the natriuretic peptides to diagnose early asymptomatic left ventricular dysfunction. Thus, diagnostic and therapeutic use of the natriuretic peptides is emerging as a new strategy to delay the natural history of progressive heart failure from its earliest phase to chronic congestive heart failure.

KW - Congestive heart failure

KW - Early asymptomatic left ventricular dysfunction

KW - Natriuretic peptides

KW - Neutral endopeptidase

UR - http://www.scopus.com/inward/record.url?scp=0032848514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032848514&partnerID=8YFLogxK

M3 - Article

C2 - 10474789

AN - SCOPUS:0032848514

VL - 10

SP - 389

EP - 394

JO - Coronary Artery Disease

JF - Coronary Artery Disease

SN - 0954-6928

IS - 6

ER -